EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic Biomarkers for Statin-Induced Myopathy

Diana Prieto-Peña iD, Juan David Urriago-Gil, Gonzalo Ocejo-Vinyals iD, Carmen García-Ibarbia, Zaida Salmon-González iD, Marta Martin-Millán, Cristina Corrales-Selaya, Verónica Pulito-Cueto iD, Raquel López-Mejías iD, Ricardo Blanco iD, Jose Luis Hernandez iD

International Journal of Molecular Sciences · 18.11.2025 · 26 (22) · 11144

DOI: 10.3390/ijms262211144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.11.2025. Verfasst von Diana Prieto-Peña und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Universitario Marqués De Valdecilla, IDIVAL, 39008 Santander, Spain. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver-Specific Organic Anion Transporter 1, Muscular Diseases, HLA-DRB1 Chains. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Statin exposure has been associated with a broad spectrum of muscle toxicity, ranging from asymptomatic creatine kinase (CK) elevation to immune-mediated necrotizing myopathy (IMNM) with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies. The mechanisms underlying these adverse effects are not fully understood, and genetic predisposition may play a role. This observational study evaluated the association of HLA-DRB1*11 and SLCO1B1 rs4149056 variants with statin-induced muscle toxicity. A total of 62 statin-exposed patients treated at a single tertiary center were included and classified as follows: IMNM with anti-HMGCR antibodies (n = 11), non-immune myotoxicity (n = 20), and statin-exposed controls without myopathy (n = 31). The mean age was 66 ± 7.5 years, and 62% were women. The frequency of the HLA-DRB1*11 allele was significantly higher in patients with anti-HMGCR IMNM compared to those with non-immune myotoxicity (81.0% vs. 25.0%; OR = 13.5, 95% CI 1.73–15.3; p < 0.01) and controls (81.0% vs. 17.2%; OR = 21.6, 95% CI 2.87–23.7; p < 0.01). No significant difference was found between the non-immune myotoxicity and control groups. Likewise, the SLCO1B1 rs4149056 variant showed no association with either IMNM or non-immune muscle toxicity. These findings confirm a strong association between the HLA-DRB1*11 allele and anti-HMGCR IMNM. This genetic marker may help to better distinguish immune-mediated from non-immune forms of statin-related myopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1Muscular DiseasesHLA-DRB1 ChainsHumansFemaleMaleAgedMiddle AgedPolymorphism, Single NucleotideGenetic MarkersGenetic Predisposition to DiseaseHydroxymethylglutaryl CoA ReductasesBiomarkers

Stichwörter der Autor:innen

HLA-DRB1*11SLCO1B1geneticsmyopathymyopathy necrotizing myopathystatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsSLCO1B1 protein, humanLiver-Specific Organic Anion Transporter 1HLA-DRB1 ChainsGenetic MarkersHydroxymethylglutaryl CoA ReductasesBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital Universitario Marqués De Valdecilla, IDIVAL, 39008 Santander, Spain.
  • Immunopathology Research Group, IDIVAL Health Research Institute of Cantabria, 39008 Santander, Spain.
  • Department of Immunology, Hospital Universitario Marqués De Valdecilla, IDIVAL, 39008 Santander, Spain.
  • Department of Internal Medicine, Hospital Universitario Marqués De Valdecilla, IDIVAL, 39008 Santander, Spain.
  • Medicine Department, University of Cantabria, 39011 Santander, Spain.

ORCID-Profile: Diana Prieto-Peña, Gonzalo Ocejo-Vinyals, Zaida Salmon-González, Verónica Pulito-Cueto, Raquel López-Mejías, Ricardo Blanco, Jose Luis Hernandez

Zitieren

APA

Prieto-Peña, D., Urriago-Gil, J. D., Ocejo-Vinyals, G., García-Ibarbia, C., Salmon-González, Z., Martin-Millán, M., Corrales-Selaya, C., Pulito-Cueto, V., López-Mejías, R., Blanco, R., & Hernandez, J. L. (2025). Genetic Biomarkers for Statin-Induced Myopathy. International Journal of Molecular Sciences, 26(22), 11144. https://doi.org/10.3390/ijms262211144

Vancouver

Prieto-Peña D, Urriago-Gil JD, Ocejo-Vinyals G, García-Ibarbia C, Salmon-González Z, Martin-Millán M, et al. Genetic Biomarkers for Statin-Induced Myopathy. International Journal of Molecular Sciences. 2025;26(22):11144. doi:10.3390/ijms262211144

BibTeX
@article{PrietoPea2025,
  author = {Prieto-Peña, Diana and Urriago-Gil, Juan David and Ocejo-Vinyals, Gonzalo and García-Ibarbia, Carmen and Salmon-González, Zaida and Martin-Millán, Marta and Corrales-Selaya, Cristina and Pulito-Cueto, Verónica and López-Mejías, Raquel and Blanco, Ricardo and Hernandez, Jose Luis},
  title = {Genetic Biomarkers for Statin-Induced Myopathy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {22},
  pages = {11144},
  doi = {10.3390/ijms262211144}
}
Kostenlos starten →